HYPERTENSION

Consensus-based recommendation for surveillance of hypertension a, b

This page is part of the PanCare follow-up recommendations for surveillance of late effects. Click here, for more information on these recommendations.

On this page you can find:

Click here, to read this recommendation in PLAIN language.

Who is at risk for hypertension?

CAYA cancer survivors treated with

  • radiotherapy to a volume exposing the kidneys, or to a volume exposing the heart and associated large vessels, including TBI
  • nephrectomy
  • ifosfamide
  • platinum based chemotherapy
  • nitrosoureas
  • immunosuppressives c

What surveillance modality should be used and at what frequency should it be performed?

  • Blood pressure
    at least every 2 years and at every long-term follow-up visit

What should be done if abnormalities are identified?

  • Evaluate other features of metabolic syndrome (including dyslipidaemia, overweight and diabetes mellitus)
  • Refer to the appropriate HCP depending on the possible cause of the hypertension

Disclaimer

While PanCare strives to provide accurate and complete information that is up-to-date as of the date of publication, we acknowledge that the sequence of referral and diagnostic tests might vary according to the local and national healthcare system logistics.

It is recognised that survivors and their healthcare professionals have the final responsibility for making decisions concerning their long-term follow-up care. As such, they may choose to either adopt these recommendations or not to do so after individual informed discussion. It is good practice to document this decision.

In addition to regular surveillance, real-time awareness and prompt reporting of new symptoms and signs is essential to the early detection and timely treatment of late effects.

No warranty or representation, expressed or implied, is made concerning the accuracy, reliability, completeness, relevance, or timeliness of this information.

The PanCare materials are free to use for anyone aiming to inform about late effects and long-term survivorship care. However, no financial advantage may be achieved. All communication should reference PanCare and link to the PanCare website.

a Further recommendations regarding blood pressure are specified in the Consensus-based recommendation for health promotion.

b Further recommendations regarding renal problems are specified in the Consensus-based recommendation for surveillance of renal problems.

c For example, cyclosporine, tacrolimus, and prolonged corticosteroids as anti-cancer treatment (at least 4 weeks continuously).